Related by context. All words. (Click for frequent words.) 77 PANSS 76 IRLS 73 Global Impression CGI 72 Impressions Improvement 72 Global Impression Severity 72 Negative Syndrome 71 Montgomery Asberg Depression 70 MADRS 69 Rating Scale MADRS 67 Scale PANSS 67 symptom severity 65 Health Assessment Questionnaire 65 Brief Psychiatric 65 YMRS 65 ADHD Rating Scale 64 HDRS 64 Alzheimer Disease Assessment 64 Visual Analog Scale 64 ADAS cog 64 Neuropsychiatric Inventory 64 ADCS CGIC 64 PANSS total 64 subscales 63 HAMD 63 Montgomery Åsberg Depression 63 ADHD RS 63 Functional Assessment 62 subscale scores 62 WOMAC pain 62 Negative Symptoms 62 Clinician Administered PTSD 62 UPDRS 62 Secondary endpoints included 62 WOMAC TM 62 Rating Scale 62 HAM D# 62 ADAS Cog 62 IBDQ 62 Hamilton Rating Scale 61 HAQ DI 61 NIH CPSI 61 nasal symptom 61 Global Impressions Severity 61 MADRS score 61 IRLS score 61 BPRS 60 depressive symptom 60 WOMAC 60 Y BOCS 60 Brief Pain 60 HADS 60 Inventory BPI 60 Unified Parkinson Disease 59 PANSS scores 59 abdominal pain abdominal discomfort 59 International Prostate Symptom 59 Dyspnea 59 mRS 59 Neuropsychiatric Inventory NPI 59 Depression Rating Scale 58 HAM D 58 EQ 5D 58 QoL 58 pain subscale 58 Expanded Disability Status 58 SGRQ 58 Functioning GAF 58 Visual Analog 58 Scale EDSS 57 Distress Scale 57 MMSE score 57 Fibromyalgia Impact Questionnaire 57 Psoriasis Area 57 non menstrual pelvic 57 Abnormal Involuntary Movement 57 Pain Intensity 57 Scale cognitive subscale 57 Rating Scale BPRS 57 subscore 57 Pain Rating Scale 57 CNS LS 57 Mania Rating Scale 57 Rating Scale UPDRS 57 Epworth Sleepiness Scale 57 Index FSFI 57 NIHSS 56 QIDS SR 56 FACIT Fatigue 56 Index CDAI 56 Visual Analogue Scale VAS 56 placebo p = 56 subscores 56 PANSS Positive 56 Severity Index 56 Physical Component 56 APACHE II 56 Depression Scale 56 achieved statistical significance 56 State Examination MMSE 55 Outcomes Study 55 Main Outcome Measures 55 Crohn Disease Activity 55 function subscale 55 HRQL 55 PSQI 55 CIBIC plus 55 Index HAQ DI 55 Mean Symptom Complex 55 Likert pain 55 interrater reliability 55 Symptom Checklist 55 Functional Outcomes 55 Geriatric Depression 55 Scale Cognitive Subscale 55 Secondary endpoints include 55 TNSS 55 SELENA SLEDAI 55 subscale 55 Chronic Illness Therapy 55 cognitive affective 55 P = .# 55 apnea hypopnea index 55 BMI z 54 ADCS ADL 54 subjective sleepiness 54 Symptom 54 affective psychosis 54 CDAI score 54 Primary endpoints 54 HRQoL 54 Cystic Fibrosis Questionnaire Revised 54 % Confidence Interval 54 Severity MSCS score 54 UPDRS motor 54 symptomatology 54 Beck Anxiety Inventory 54 NYHA functional class 54 DAS# [002] 54 HRQOL 54 Key secondary endpoints 54 Assessment Scale 54 emotional lability 54 Score TOS 54 Oswestry Disability Index 54 Index WOMAC 53 CDAI 53 Seattle Angina Questionnaire 53 Severity Index PASI 53 Severity 53 daytime somnolence 53 secondary endpoint 53 Symptom Score 53 Respiratory Symptoms 53 mTSS 53 clinically meaningful improvement 53 lumbar spine BMD 53 Disease Activity 53 p = .# [002] 53 Physical Function 53 Subscale 53 Index CDAI score 53 CFQ R 53 p = #.# [002] 53 HOMA IR 53 statistically significant improvement 53 adjunctive ABILIFY 53 Numeric Rating Scale 53 Secondary endpoints 53 preoperative PSA 53 DAS# scores 53 Depressive Symptomatology 53 Score IPSS 52 Glasgow Coma Scale 52 prespecified secondary 52 mg TID 52 placebo p 52 Visual Analogue Scale 52 VFQ 52 tapentadol ER 52 Timed Walk 52 Stroke Scale NIHSS 52 dactylitis 52 desvenlafaxine succinate 52 BPH symptom 52 Score DAS 52 Rating Scale IRLS 52 demonstrated statistically significant 52 linaclotide treated 52 Hamilton Anxiety Scale 52 Depression Inventory 52 Total Nasal Symptom 52 MMSE 52 euthymic 52 clinically meaningful improvements 52 Severity Scale 52 -#.# mg dL [001] 52 liver histology 52 Negative Symptom Scale 52 Cronbach alpha 52 ASIA Impairment 52 -#.# ± [002] 52 depressive symptomatology 52 oxycodone CR 52 Edinburgh Postnatal Depression 52 SSRI SNRI 52 Change PGIC 51 biopsy Gleason 51 Main Outcome Measure 51 extrapyramidal symptoms 51 -#.# mg dL [002] 51 posttreatment 51 p = #.# [004] 51 secondary efficacy endpoint 51 dyspnea 51 MSLT 51 IIEF 51 systolic BP 51 Ocular Surface Disease 51 erection hardness 51 clinical meaningfulness 51 Rosenberg Self Esteem 51 GERD symptom 51 BPH Symptom Score 51 Depressive Symptoms 51 retinal thickness 51 Postoperative 51 adjunctive placebo 51 nausea photophobia 51 baseline PASI 51 psychometric properties 51 subthreshold depression 51 Symptom severity 51 EDSS 51 PCWP 51 urinary N telopeptide 51 dyspnoea 51 IPSS 51 6MWD 51 Symptom Severity 51 KOOS 51 psychosocial functioning 51 8mg/kg 51 Symptom Scale 51 Status Scale EDSS 51 Treatment Outcome 51 CIBIC + 51 mcg QD 51 Erectile Function IIEF 51 fasting plasma glucose FPG 51 Likert 50 Depression Inventory BDI 50 Likert type 50 4mg/kg 50 moderate renal impairment 50 albumin excretion rate 50 prospectively stratified 50 Stroke Scale 50 CI -#.# 50 ETDRS 50 mg BID dose 50 Clinician Interview Based 50 covariate 50 DLQI 50 AUA Symptom Score 50 intraobserver 50 elevated transaminases 50 tolterodine ER 50 demonstrated clinically meaningful 50 Somnolence 50 mg XP# 50 nighttime awakenings 50 constipation nausea 50 sUA 50 placebo fluoxetine 50 solifenacin 50 hyperarousal 50 SSRI citalopram 50 CSBM 50 CrCl 50 spontaneous bowel movements 50 sd = 50 Demonstrated Significant 50 dichotomized 50 Erectile Function 50 % CI #.#-#.# [006] 50 Psychological Distress 50 DAS# CRP 50 pulmonary capillary wedge 50 EDSS score 50 erythrocyte sedimentation rate 50 meta regression 50 TEAEs 50 SF #v# 49 Orthostatic Hypotension 49 certolizumab 49 convergent validity 49 interobserver 49 budesonide pMDI 49 bronchial hyperresponsiveness 49 vitreous haze 49 PASI scores 49 undetectable HBV DNA 49 MMSE scores 49 EDEMA3 trial 49 comorbid anxiety 49 venlafaxine XR 49 euthymic patients 49 Sensitivity specificity 49 #.#/#.# mmHg [001] 49 amisulpride 49 Anxiety Rating Scale 49 Score DAS# 49 CI #.#-#.# [001] 49 Non inferiority 49 headache nasopharyngitis 49 neurocognitive function 49 aminotransferase levels 49 PERMP 49 CORE OM 49 statistically significant reduction 49 point Likert scale 49 comorbid 49 Acute Physiology 49 Clinical Dementia 49 Ashworth Scale 49 treat NNT 49 NPRS 49 Hopkins Symptom Checklist 49 baseline FEV 49 Endocrine Therapy 49 Outcome Measures 49 Depressive symptoms 49 Comorbidities 49 MoxDuo TM IR 49 Pearson correlation coefficient 49 NNT = 49 postprocedure 49 parkinsonian 49 attain statistical significance 49 enthesitis 49 F FDG PET 49 intima media thickness 49 Injury Severity Score 49 akinesia 49 retest reliability 49 posttest 49 Treatment Diabetic Retinopathy 49 untreated psychosis 49 NPH insulin 49 neuroleptic 49 Comorbidity 49 CGIC 49 subsyndromal 49 UPDRS Part III 49 Wechsler Adult 49 tipranavir r 49 p = 49 confidence intervals CIs 49 intima media thickness IMT 49 Helps Relieve 49 Apidra ® 49 annualized relapse 49 -#.# mm Hg 49 Thrombolysis 49 morphometric vertebral fractures 49 Preoperatively 49 NIS LL 49 REYATAZ r arm 49 Scale 49 Visual acuity 48 QTc intervals 48 placebo 48 biochemical recurrence 48 nonsignificant 48 headache abdominal pain 48 primary efficacy endpoint 48 creatinine ratio 48 Study ETDRS 48 Solid Tumors 48 semiquantitative 48 overnight polysomnography 48 trough FEV1 48 intraclass correlation coefficient 48 Clinically meaningful 48 achieved ACR# 48 Assessment Questionnaire 48 paresthesias 48 hypoglycemic events 48 Postoperatively 48 lopinavir r arm 48 elevated ALT 48 logistic regression 48 dapagliflozin plus 48 Pharmacokinetic parameters 48 dizziness somnolence 48 Ejection Fraction 48 AUA BPH Symptom Score 48 postintervention 48 hemodynamic measurements 48 Loss Severity 48 Patients Receiving 48 sleep onset WASO 48 symptomatic VTE 48 CHADS2 48 racemic albuterol 48 â ‰ ¥ 48 tertile 48 Anxiety Depression 48 fasting plasma glucose 48 McGill Pain Questionnaire 48 mcg BID 48 ANCOVA 48 hepato renal syndrome 48 = #.#-#.# 48 Likert scale 48 Health Questionnaire PHQ 48 hypersomnia 48 depressive symptoms 48 Hepatitis C Antiviral 48 Depression Anxiety 48 function subscales 48 PSADT 48 ‰ ¥ 48 intravascular hemolysis 48 Scale EDSS score 48 endometrial thickness 48 lispro 48 clinically meaningful reductions 48 QTc 48 infliximab monotherapy 48 #mg/day [001] 48 % CI #.#-#.# [007] 48 bortezomib refractory 48 ≥ 48 refractory ischemia 48 lowest tertile 48 fasting insulin 48 odds ratios ORs 48 vasomotor 48 somatic symptoms 48 systolic function 48 clinically meaningful 48 OSDI 48 Fasting plasma glucose 48 prespecified 48 diastolic BP 48 ACR# response 48 ANOVA 48 Showed Significant 48 ACR# ACR# 48 RLAI 47 WOMAC scores 47 unfractionated heparin UFH 47 intraclass correlation coefficients 47 serum phosphorous 47 concomitant medications 47 insulin detemir 47 + PH# 47 INVEGA ® 47 β blocker 47 plasma leptin 47 Coronary Artery Calcium 47 NIHSS score 47 1mg dose 47 nausea somnolence 47 postop 47 symptom exacerbation 47 Scale Revised 47 p = NS 47 CANCIDAS 47 mg p = 47 constipation dizziness 47 ischemia driven 47 Interrater reliability 47 HbA 1c 47 nonfatal MI 47 -#.# ± [001] 47 statistically significant p = 47 Persistent Sleep 47 Negative Symptom Scale PANSS 47 EBMT criteria 47 Secondary efficacy endpoints 47 virological response 47 exploratory endpoints 47 receiving APTIVUS r 47 Zometa hazard 47 PHQ 9 47 statistically significant 47 multivariate Cox 47 QRS duration 47 ß = 47 fractional anisotropy 47 SLEDAI 47 Histologic 47 virologic response 47 plus methotrexate 47 divalproex sodium 47 CRp 47 Exclusion criteria 47 diarrhea flatulence 47 urate lowering therapy 47 divalproex 47 Wechsler Memory 47 fractional shortening 47 EF Domain 47 preoperatively 47 guanfacine extended release 47 bothersome symptom 47 LVEF 47 HbA 1c levels 47 -#.# log# copies mL 47 schizophrenia schizoaffective disorder 47 Ischemic Stroke 47 Diabetic Foot Ulcer 47 haematologic 47 Ishak fibrosis score 47 vitreous floaters 47 psychopathological symptoms 47 nonobese 47 Wechsler Intelligence 47 Cockcroft Gault 47 mean ± SEM 47 EORTC QLQ C# 47 % CI #.#-#.# [003] 47 confidence interval CI 47 ecchymosis 47 diameter stenosis 47 State Trait Anxiety 47 apnea hypopnea 47 incontinence episodes 47 receiving VICTRELIS 47 glycosylated hemoglobin HbA1c 47 hemoglobin A1c levels 47 phonophobia 47 RECIST Response Evaluation Criteria 47 aminotransferases 47 LV ejection fraction 47 composite endpoint 47 Improves Quality 47 Fecal Incontinence 47 fatigue abdominal pain 47 HBeAg seroconversion 47 logistic regression model 47 unpaired t 47 ALS Functional 47 DAS# remission 47 gadolinium enhancing lesions 47 pulmonary exacerbations 47 mg BID 47 creatinine clearance 47 Cardiac Resynchronization 47 rCBF 47 Myocardial Infarction TIMI 47 HbA1c levels 47 mg QD 47 interobserver reliability 47 dyspareunia 47 ug kg 47 Elderly Patients 47 oxygen desaturation 47 activated partial thromboplastin 47 Univariate 47 Left Ventricular Ejection Fraction 47 locomotor activity 47 serum cortisol 47 carotid IMT 47 ziprasidone 47 nicardipine 47 x ULN 47 Incontinence Impact Questionnaire 47 Functioning Scale 47 events TEAEs 47 serum aminotransferase levels 47 Oral Fingolimod 47 CONCERTA ® 47 BILAG 46 Desvenlafaxine Succinate 46 cardiac autonomic 46 Univariate analysis 46 #q# deletion syndrome 46 nasopharyngitis headache 46 Non Responders 46 neurologic symptoms 46 laboratory abnormalities 46 secondary endpoints 46 Adult ADHD 46 adefovir treated 46 neutropaenia 46 serum potassium 46 virologic breakthrough 46 Clinical Outcome 46 ventricular tachyarrhythmia 46 docetaxel pretreated 46 CPAP adherence 46 Kaplan Meier method 46 poststroke 46 FDG-PET/CT 46 ALT AST 46 df = 46 secondary efficacy endpoints 46 alanine aminotransferase 46 PREZISTA r arm 46 PLMS 46 Sleep Disturbance 46 neutropenia dehydration dyspnea 46 HAM D# scores 46 gadolinium enhancing 46 #.#/#.# mm Hg [001] 46 Maslach Burnout Inventory 46 Hematologic toxicity 46 urinary albumin 46 orthostatic 46 QOL 46 #.#ng/ml 46 psychiatric comorbidity 46 EDSS scores 46 Dissociation 46 HBeAg negative patients 46 statistically significant p 46 methotrexate monotherapy 46 Therapy Reduces 46 Apgar scores 46 Pred Forte 46 SCr 46 somatostatin analog 46 nerve conduction velocity 46 placebo PBO 46 preintervention 46 intact parathyroid hormone 46 lipid parameters 46 echocardiographic parameters 46 corneal staining 46 QD dosing 46 cerebral perfusion 46 plus MTX 46 mean baseline HbA1c 46 prednisone prednisolone plus 46 Predictors 46 left ventricular diastolic 46 p = #.# [003] 46 psychosocial variables 46 NSAID associated 46 quetiapine 46 AUC0 46 Kruskal Wallis test 46 subtest 46 mg tid 46 UPDRS scores 46 CR CRu 46 -#.# log# 46 multivariable Cox 46 Cronbach 46 variance ANOVA 46 Kaplan Meier analysis 46 atheroma volume 46 comorbid conditions 46 coronary stenosis 46 affective psychoses 46 analgesic efficacy 46 Profile SEP 46 quetiapine risperidone 46 analgesic medications 46 ARB telmisartan 46 Satisfaction Questionnaire 46 hematologic parameters 46 Target Lesion Revascularization TLR 46 Suicidal ideation 46 STAI 46 neurologic dysfunction 46 Questionnaire 46 bosentan 46 antibody titer 46 univariate 46 HbA1C levels 46 correlation coefficients 46 comorbidity 46 #mg BID [003] 46 subtests 46 Symptom Improvement 46 progression TTP 46 serologically active patients 46 rimonabant #mg 46 tic severity 46 nausea dizziness vomiting 46 Pharmacodynamic 46 events AEs 46 univariate analysis 46 ACTEMRA TM 46 CIMZIA TM certolizumab pegol 46 events MACE 46 NSTEMI 46 hepatic enzyme 46 Exacerbations 46 confirmed CCyR 46 Comorbid 46 HAQ 46 cortical atrophy 46 somnolence sleepiness 46 prodromal symptoms 46 Kaplan Meier survival 46 Child Behavior Checklist 46 aspartate aminotransferase AST 46 Charlson Comorbidity Index 46 PSA nadir 46 Operative mortality 46 System IPSS 46 syndromal 46 plus prednisone 46 binary restenosis 46 multivariable adjusted 46 mean baseline A1C 46 pharmacodynamic PD 46 #.#/#.# mm Hg [003] 45 abacavir lamivudine 45 Obsessive Compulsive Scale 45 tirofiban 45 interrater 45 ejaculatory function 45 hours postdose 45 estimated GFR 45 ATACAND 45 WAIS III 45 Mammographic 45 CHADS 45 QTcF 45 nondiabetic patients 45 Statistically Significant 45 Relapsing Remitting Multiple Sclerosis 45 Partial Response 45 Pharmacokinetics PK 45 ventricular repolarization 45 Capacity FVC 45 pruritis 45 PaO 2 45 maximal treadmill 45 leukopenia 45 mm Hg diastolic 45 hypochondriasis 45 adenotonsillectomy 45 XIENCE V PROMUS Stent 45 plasma lipids 45 tier Saffir Simpson 45 moderate hepatic impairment 45 mg Pycnogenol 45 rheumatoid factor 45 Meta Analysis 45 Completeness 45 CCyR 45 lactate dehydrogenase LDH 45 chills fever headache 45 FFNS 45 fatal anaphylactic 45 plasma HCV RNA 45 postoperative complication 45 State Exam MMSE 45 PDSS 45 TRUS 45 hip BMD 45 primary efficacy endpoints 45 postdose 45 serum urate 45 arterial oxygen saturation 45 incidence ≥ 45 ejaculatory control 45 logistic regression analysis 45 nausea emesis 45 genital arousal 45 prospectively defined 45 Coleman Liau 45 MADRS scores 45 affective disorders 45 STRATEGY FOR AN OPEN 45 FDG uptake 45 conditional logistic regression 45 highest tertile 45 Subgroup Analysis 45 aPTT 45 FACIT 45 baseline HbA1c 45 transaminases 45 splenectomized patients 45 TURBT 45 tiotropium 45 Shows Efficacy 45 Anxiety Scale 45 Demonstrates Efficacy 45 mild renal insufficiency 45 zonisamide SR 45 suicide attempters 45 sensitivity specificity 45 #.#mg/dL 45 IU ml 45 adenoma recurrence 45 Poisson regression 45 corrected QT interval 45 Stent thrombosis 45 agitation hallucinations 45 log# copies mL 45 endoscopic remission 45 β = 45 Bonferroni correction 45 exhaled nitric oxide 45 CR nPR 45 r = 45 treatment emergent AEs 45 glycosylated hemoglobin levels 45 posttransplant 45 morbidity mortality 45 tissue oxygenation 45 fructosamine 45 Hb A1C 45 ALSFRS R 45 Lower Limb 45 Abdominal Pain 45 % CI #.#-#.# [004] 45 tumor progression TTP 45 FEV ^ sub 45 fatigue asthenia 45 Multiple Ascending Dose 45 quartiles 45 estimated glomerular filtration 45 postinjury 45 treatment emergent adverse 45 NCQA accreditation surveys 45 Clinically significant 45 mcg linaclotide 45 serum magnesium 45 pharmacodynamic parameters 45 Female Sexual Function 45 hyperalgesia 45 IIIa inhibitor 45 LEXIVA r 45 serum BDNF 45 ropivacaine 45 Reported Outcome 45 statistically significant differences 45 lactate dehydrogenase 45 hypophosphatemia 45 univariate analyzes 45 HbA 1C 45 leukocyte counts 45 lipid profiles 45 Logistic regression 45 Descriptive statistics 45 mg RDEA# 45 Free Survival PFS 45 transcranial Doppler ultrasound 45 Diagnostic Criteria 45 methacholine challenge 45 aspartate aminotransferase 45 lymphopenia 45 Platelet counts 45 electroencephalographic 45 Nocturia 45 lamivudine refractory patients 45 elevated creatinine 44 ± SD 44 plasma cortisol 44 alfuzosin 44 Epidemiological Studies Depression 44 Cardiorespiratory fitness 44 TMC# r 44 T2 lesion volume 44 μg kg 44 recurrent venous thromboembolism 44 APTIVUS r 44 rhinoconjunctivitis 44 Treated Patients 44 IKDC 44 mL/min/#.# m 2 44 postoperative AF 44 abdominal pain flatulence 44 Flu Cy 44 alanine aminotransferase ALT 44 Major Adverse Cardiac 44 PSA kinetics 44 prolonged QT intervals 44 Predict Risk 44 Cmax 44 Evaluable 44 Suboptimal 44 deep venous thromboses 44 achieved PASI 44 mg qd 44 Median PFS 44 serum leptin 44 baseline A1C 44 plus OBT 44 unresectable HCC 44 aromatase inhibitor therapy 44 p = .# [001] 44 Thal Dex 44 citalopram 44 salivary cortisol 44 Scale CNS 44 left ventricular systolic 44 saline placebo 44 colesevelam 44 severe hypoglycemic 44 bispectral index BIS 44 generalized anxiety disorder GAD 44 Lucentis monotherapy 44 UACR 44 febrile neutropenia 44 mg kg belimumab 44 Insomnia Severity Index 44 SGPT 44 flow mediated dilation 44 pT3 44 depression irritability 44 Perceived Stress Scale 44 response CCyR 44 Double Blind Randomized 44 premorbid 44 abnormal ejaculation 44 acute subacute 44 daytime drowsiness 44 oral antidiabetes 44 Sustained virologic response 44 apolipoprotein B 44 Risk Stratification 44 RAPAFLO R 44 platelet reactivity 44 Long Term Efficacy 44 Bonferroni 44 oxycodone IR 44 verbal fluency 44 T2DM 44 cells uL 44 chi squared 44 electrophysiologic 44 dosed intravenously 44 corticosteroid dose 44 serum lipid 44 FOLFOX4 44 Beta Blockers 44 schizotypal 44 Subgroup analysis 44 alexithymia 44 Meta analyzes 44 ug dose 44 postoperative mortality 44 death reinfarction 44 waist circumference WC 44 psychiatric comorbidities 44 psychophysiological 44 mL kg 44 Serum concentrations 44 SBP DBP 44 multivariate analyzes 44 obstructive CAD 44 carotid intima media 44 cerebral somatic oximeter 44 fasting plasma 44 plus octreotide LAR 44 HBeAg 44 ACR# [002] 44 Sociodemographic 44 multivariable analysis 44 mRNA expression 44 IBS symptoms 44 cognitive domains 44 perceptual reasoning 44 Generalized Anxiety Disorder 44 C Reactive Protein 44 QT interval prolongation 44 Suicidality 44 neurologic progression 44 hemoglobin A1c HbA1c 44 neutropenia thrombocytopenia 44 glomerular filtration 44 esophageal carcinoma 44 escitalopram Lexapro 44 Efficacy 44 serum sodium 44 Sleep Disturbances 44 CAHPS 44 extensive metabolizers 44 Subjective 44 CRQ 44 mEq L 44 primary endpoints 44 erythema 44 Endarterectomy 44 FEV1 44 Kaplan Meier estimates 44 DSM IV Axis 44 serum ALT 44 rearfoot 44 median PFS 44 Cognitive Function 44 TIMP 1 44 Cystatin C 44 Functional Capacity 44 OGTT 44 neurocognitive functioning 44 ST Segment Elevation 44 pretest probability 44 severe exacerbations